ARGNF News and Press, Argen X NV From 06/01/23

2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...

2023-05-10 04:56:00 ET Summary Baron Fifth Avenue Growth Fund gained 19.7% during the first quarter, which compares to gains of 14.4% for the Russell 1000 Growth Index and 7.5% for the S&P 500 Index, the Fund’s benchmarks. The Fund is constructed on a bottom-up basis wi...

2023-05-06 17:57:09 ET argenx SE (ARGX) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz -...

2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...

$218 million in first quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART received marketing authorization in Israel through partnership with Medison 88 events achieved in ADHERE trial; topline data now expected in July 2023 Enrollment completed...

May 3 , 2023 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders he...

2023-05-02 17:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund® climbed 17.96% (Institutional S...

May 2 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a firesid...

Amsterdam, the Netherlands – [0 4 / 18 /2023] argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will present six abstracts further demonstr...

Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Amsterdam, the Netherlands...